Clinical TrialAug 3, 2026, 08:35 AM
AIM ImmunoTech Completes Dosing in Phase 2 DURIPANC Trial Ahead of Schedule
AI Summary
AIM ImmunoTech Inc. announced the completion of dosing for the final subject in its Phase 2 DURIPANC clinical trial, evaluating Ampligen in combination with Imfinzi for metastatic pancreatic cancer, ahead of schedule. The company anticipates Primary Endpoint analysis to begin in December 2026 and topline results in Q1 2027. This follows encouraging exploratory observations from a Named Patient Program where Ampligen showed a median Overall Survival of 34.8 months in a specific patient subset, compared to 12.5 months for historical controls.
Key Highlights
- Final subject received last dose of Ampligen in Phase 2 DURIPANC trial ahead of schedule.
- DURIPANC Primary Endpoint analysis anticipated to begin in December 2026.
- Topline results for DURIPANC trial are anticipated in Q1 2027.
- DURIPANC Overall Survival Endpoint analysis expected to begin in June 2027.
- Named Patient Program showed median Overall Survival of 34.8 months vs. 12.5 months for controls in a patient subset.
Price Impact
More from AIM